Clinical Trial Update: Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of sintilimab and anlotinib in advanced non-small cell lung cancer with EGFR uncommon mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED